Zometa is a bisphosphonate, or bone hardener/strengthener. Administered by IV, Zometa has traditionally been used in patients with extreme osteoporosis, or multiple myeloma patients who have suffered bone damage from their cancer. Recent studies have confirmed Zometa has anti-myeloma properties as well. Here is an article about a study from last year, showing even more impressive activity against metastasised lung cancer:

Oncology NEWS – zoledronic acid (Zometa) increases overall survival in lung cancer patients with bone metastases
August 24, 2009
The addition of zoledronic acid (Zometa) increases overall survival in lung cancer patients with bone metastases, according to researchers at Aristotle University of Thessaloniki and G. Papanikolaou Hospital in Greece.

For this study, they enrolled 144 stage IV lung cancer patients with evidence of metastases on bone scans.

Of the 144, a total of 87 reported bone pain and were treated with zoledronic acid (4 mg by IV) every 21 days. The remaining patients did not receive treatment with the bisphosphonate.

All patients underwent chemotherapy with docetaxel (Taxotere; 100 mg/m2) and carboplatin (AUC = 6). Those who received zoledronic acid had a statistically significant longer survival (P < .01) when compared with those who did not.The longer the period of receiving zoledronic acid, the better effect on survival and time-to-progression, wrote Kostantinos Zarogoulidis, MD, and colleagues in the International Journal of Cancer (125:1705-1709, 2009).This is a good thing. Zometa fights cancer and improves bone density at the same time. Some drugs are worth the cost.Feel good and keep smiling! Pat

Leave a Reply